SCHEMBL7301570

SCHEMBL7301570

COc1cccc(Oc2c(Cl)nc(-c3cccs3)nc2N(CC(C)C)S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 6/20 0.43
LMNA P02545 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PTPRB P23467 1/20 0.39
NR1H2 P55055 1/20 0.38
MAPK1 P28482 2/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
MCL1 Q07820 4/20 0.37
RORC P51449 1/20 0.36
PGR P06401 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7300166 0.87 DHPS (0.38) GBA1MEN1KMT2ARORC
SCHEMBL7321798 0.86 GBA1 (0.40) GBA1LMNAKDM4EALDH1A1MAPT
SCHEMBL7326214 0.81 NR1H2 (0.40) LMNAKDM4EALDH1A1MAPTHPGD
SCHEMBL9423667 0.77 NPC1 (0.52) GBA1LMNAKDM4EALDH1A1MAPT
SCHEMBL7293953 0.74 MCL1 (0.40) KDM4EALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL7303989 0.74 DHPS (0.47) HTTMCL1
SCHEMBL7297143 0.74 DHPS (0.42) MCL1RORC
SCHEMBL7328142 0.74 EDNRA (0.48)
SCHEMBL7302917 0.73 EDNRA (0.51)
SCHEMBL7332509 0.72 RORC (0.38) KDM4EALDH1A1MAPTHPGDNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0526708-B1 Sulfonamide, preparation and use thereof as medicine and intermediate HOFFMANN LA ROCHE (CH) 2000-10-18 EP disclosed
EP-0526708-A1 Sulfonamide, preparation and use thereof as medicine and intermediate F. HOFFMANN-LA ROCHE AG (CH) 1993-02-10 EP disclosed